INT313753

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 10
Total Number 10
Disease Relevance 3.76
Pain Relevance 3.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

generation of precursor metabolites and energy (ACOX1) mitochondrion (ACOX1) small molecule metabolic process (ACOX1)
peroxisome (ACOX1) lipid metabolic process (ACOX1) cytoplasm (ACOX1)
ACOX1 (Homo sapiens)
Pain Link Frequency Relevance Heat
cINOD 676 99.88 Very High Very High Very High
aspirin 198 99.38 Very High Very High Very High
diclofenac 9 99.12 Very High Very High Very High
cytokine 9 85.52 High High
withdrawal 9 70.72 Quite High
Paracetamol 27 51.92 Quite High
rheumatoid arthritis 36 31.36 Quite Low
Migraine 36 29.36 Quite Low
alcohol 9 5.00 Very Low Very Low Very Low
agonist 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Breast Cancer 468 99.40 Very High Very High Very High
Cancer 73 95.40 Very High Very High Very High
Carcinoma 9 89.92 High High
Disorder Of Lipid Metabolism 12 88.80 High High
Body Weight 71 86.48 High High
Obesity 142 85.20 High High
Esophageal Cancer 9 81.24 Quite High
Gastrointestinal Neoplasms 9 79.44 Quite High
INFLAMMATION 37 75.32 Quite High
Endometriosis (extended) 29 75.20 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Overall, our findings on ever/never use and recent versus former use of sCox-2 inhibitors do not support a protective effect of sCox-2 inhibitors on breast cancer risk.
Negative_regulation (inhibitors) of sCox-2 associated with breast cancer
1) Confidence 0.45 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2879557 Disease Relevance 0.67 Pain Relevance 0.27
Some NSAIDs are more potent against Cox-1 (for example, aspirin), others have greater affinity for Cox-2 (sCox-2 inhibitors), while others are relatively non-selective (for example, naproxen) [15].
Negative_regulation (inhibitors) of sCox-2 associated with aspirin and cinod
2) Confidence 0.33 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2879557 Disease Relevance 0.85 Pain Relevance 0.87
The Danish National Health Service provides free tax-supported healthcare to all residents of the country and refunds part of patient expenditures on most prescribed drugs, including aspirin, non-selective NA-NSAIDs, and sCox-2 inhibitors.
Negative_regulation (inhibitors) of sCox-2 associated with aspirin and cinod
3) Confidence 0.33 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2879557 Disease Relevance 0.20 Pain Relevance 0.45
We grouped both newer and older sCox-2 inhibitors together.
Negative_regulation (inhibitors) of sCox-2
4) Confidence 0.33 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2879557 Disease Relevance 0.20 Pain Relevance 0.29
We identified prescriptions for the following sCox-2 inhibitors: newer sCox-2 inhibitors (celecoxib M01AH01, rofecoxib M01AH, valdecoxib M01AH03, etoricoxib M01AH05), and older sCox-2 inhibitors (lornoxicam M01AC05, diclofenac M01AB05, meloxicam M01AC06).
Negative_regulation (inhibitors) of sCox-2 associated with diclofenac
5) Confidence 0.33 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2879557 Disease Relevance 0.18 Pain Relevance 0.17
Selective Cox-2 inhibitors include the older sCox-2 inhibitors (for example, meloxicam), and newer sCox-2 inhibitors (for example, rofecoxib, celecoxib, and so on), which became available in Denmark in 1999.
Negative_regulation (inhibitors) of sCox-2
6) Confidence 0.33 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2879557 Disease Relevance 0.18 Pain Relevance 0.39
We identified prescriptions for the following sCox-2 inhibitors: newer sCox-2 inhibitors (celecoxib M01AH01, rofecoxib M01AH, valdecoxib M01AH03, etoricoxib M01AH05), and older sCox-2 inhibitors (lornoxicam M01AC05, diclofenac M01AB05, meloxicam M01AC06).
Negative_regulation (inhibitors) of sCox-2 associated with diclofenac
7) Confidence 0.33 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2879557 Disease Relevance 0.18 Pain Relevance 0.15
Overall, our findings on ever/never use and recent versus former use of sCox-2 inhibitors do not support a protective effect of sCox-2 inhibitors on breast cancer risk.
Negative_regulation (effect) of sCox-2 associated with breast cancer
8) Confidence 0.33 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2879557 Disease Relevance 0.63 Pain Relevance 0.29
We identified prescriptions for the following sCox-2 inhibitors: newer sCox-2 inhibitors (celecoxib M01AH01, rofecoxib M01AH, valdecoxib M01AH03, etoricoxib M01AH05), and older sCox-2 inhibitors (lornoxicam M01AC05, diclofenac M01AB05, meloxicam M01AC06).
Negative_regulation (inhibitors) of sCox-2 associated with diclofenac
9) Confidence 0.33 Published 2010 Journal Breast Cancer Res Section Body Doc Link PMC2879557 Disease Relevance 0.18 Pain Relevance 0.15
Coadministration of fenofibrate and E2 significantly decreased ACOX, HD, and thiolase mRNA levels compared with fenofibrate treatment.
Negative_regulation (decreased) of ACOX
10) Confidence 0.04 Published 2010 Journal PPAR Research Section Body Doc Link PMC2943125 Disease Relevance 0.50 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox